181 related articles for article (PubMed ID: 38168062)
1. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo.
Najumudeen AK; Fey SK; Millett LM; Ford CA; Gilroy K; Gunduz N; Ridgway RA; Anderson E; Strathdee D; Clark W; Nixon C; Morton JP; Campbell AD; Sansom OJ
Nat Commun; 2024 Jan; 15(1):100. PubMed ID: 38168062
[TBL] [Abstract][Full Text] [Related]
2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
4. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
[TBL] [Abstract][Full Text] [Related]
5. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
[TBL] [Abstract][Full Text] [Related]
6. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells.
Fan HY; Liu Z; Paquet M; Wang J; Lydon JP; DeMayo FJ; Richards JS
Cancer Res; 2009 Aug; 69(16):6463-72. PubMed ID: 19679546
[TBL] [Abstract][Full Text] [Related]
7. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.
Collins MA; Bednar F; Zhang Y; Brisset JC; Galbán S; Galbán CJ; Rakshit S; Flannagan KS; Adsay NV; Pasca di Magliano M
J Clin Invest; 2012 Feb; 122(2):639-53. PubMed ID: 22232209
[TBL] [Abstract][Full Text] [Related]
9. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
11. Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.
László L; Kurilla A; Takács T; Kudlik G; Koprivanacz K; Buday L; Vas V
Cells; 2021 Mar; 10(3):. PubMed ID: 33802849
[TBL] [Abstract][Full Text] [Related]
12. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
13. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
14. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
15. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
16. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Burgess MR; Hwang E; Mroue R; Bielski CM; Wandler AM; Huang BJ; Firestone AJ; Young A; Lacap JA; Crocker L; Asthana S; Davis EM; Xu J; Akagi K; Le Beau MM; Li Q; Haley B; Stokoe D; Sampath D; Taylor BS; Evangelista M; Shannon K
Cell; 2017 Feb; 168(5):817-829.e15. PubMed ID: 28215705
[TBL] [Abstract][Full Text] [Related]
17. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic
Boutin AT; Liao WT; Wang M; Hwang SS; Karpinets TV; Cheung H; Chu GC; Jiang S; Hu J; Chang K; Vilar E; Song X; Zhang J; Kopetz S; Futreal A; Wang YA; Kwong LN; DePinho RA
Genes Dev; 2017 Feb; 31(4):370-382. PubMed ID: 28289141
[TBL] [Abstract][Full Text] [Related]
19. Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
Trinidad AG; Whalley N; Rowlinson R; Delpuech O; Dudley P; Rooney C; Critchlow SE
Oncogene; 2017 Nov; 36(44):6164-6176. PubMed ID: 28692044
[TBL] [Abstract][Full Text] [Related]
20. Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy.
Smakman N; Veenendaal LM; van Diest P; Bos R; Offringa R; Borel Rinkes IH; Kranenburg O
Oncogene; 2005 Dec; 24(56):8338-42. PubMed ID: 16091732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]